Tesaro is celebrating the approval of its cancer-treatment drug by seeking a sale, per WSJ.
Why it matters: Tesaro makes cancer drugs, and a sale could induce a bidding war among other drug companies who want a piece of the competitive space that has also commanded extremely high prices.
The numbers: The company most recently had a market value of $7.4 billion, which means should a bidder be approved, the sale could be as high as $9 billion, WSJ notes.
The drug: It's called Zejula and it helps treat ovarian cancer. Analysts estimated that Zejula sales could hit $1.9 billion by 2022, but only if it expands to treat other types of cancer (like breast cancer).